Scarica l'app Stockscreener
0.8026
11.70%
-0.1063
Dopo l'orario di chiusura:
.82
0.0174
+2.17%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TPST Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.9089
Aprire:
$0.95
Volume 24 ore:
362.03K
Relative Volume:
1.89
Capitalizzazione di mercato:
$13.27M
Reddito:
-
Utile/perdita netta:
$-43.10M
Rapporto P/E:
-0.1292
EPS:
-6.2098
Flusso di cassa netto:
$-26.38M
1 W Prestazione:
-23.56%
1M Prestazione:
-22.83%
6M Prestazione:
-66.56%
1 anno Prestazione:
-84.72%
Intervallo 1D:
$0.80
$0.95
Intervallo di 1 settimana:
$0.80
$1.05
Portata 52W:
$0.80
$6.115
Tempest Therapeutics Inc Stock (TPST) Company Profile
Nome
Tempest Therapeutics Inc
Settore
Industria
Telefono
415-798-8589
Indirizzo
2000 SIERRA POINT PARKWAY, BRISBANE
Compare TPST vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TPST
Tempest Therapeutics Inc
|
0.8026 | 15.03M | 0 | -43.10M | -26.38M | -6.2098 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tempest Therapeutics Inc Stock (TPST) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-22 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-04-10 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-04-10 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| 2024-03-14 | Iniziato | Scotiabank | Sector Outperform |
| 2024-02-08 | Iniziato | Jefferies | Buy |
Tempest Therapeutics Inc Borsa (TPST) Ultime notizie
Tempest Therapeutics secures $50M equity purchase agreement with Lincoln Park - scanx.trade
Tempest Therapeutics CEO to present at H.C. Wainwright Global Investment Conference - Bitget
A biotech CEO will speak Sept. 15; Tempest will archive the webcast - Stock Titan
Tempest to Present at the H.C. Wainwright 28th Annual Global Investment Conference - Yahoo Finance
Tempest Therapeutics, Inc. SEC Filing (Sep 1, 2026) - Stock Titan
Tempest Therapeutics (TPST) Slips 1.85% to $1.06 as Shares Test Support at $1.01Cup and Handle - siam.in
Tempest TherapeuticsJustin Trojanowski To Resign As Principal Financial Officer And Principal Accounting Officer Effective Sept 1SEC Filing - TradingView
Tempest (TPST) Results at a Glance: Reported EPS Misses Expectations at the Close; Trading Move: The Stock Records a 1.96% Increase in Latest TradingProfit Guidance Range - vinanet.vn
Tempest Therapeutics files prospectus for sale of 8.9 million shares - scanx.trade
Tempest Therapeutics (NASDAQ: TPST) lines up $50M stock facility that may heavily dilute holders - Stock Titan
Tempest (TPST) Results Versus Estimates: The EPS Result Is Below Expectation in Latest Trading; Latest Reaction: The Stock Loses 4.58% in the Available RecordProfit Recovery Report - vinanet.vn
Tempest partners Senlang to advance TPST-4003 in China trial - scanx.trade
Form 8K Tempest Therapeutics Inc For: 18 August By Investing.com - Investing.com South Africa
Tempest Therapeutics adjourns special meeting, sets new date for stockholder vote - Investing.com
Tempest Therapeutics Adjourns Special Stockholder Meeting Again - TipRanks
TPST Q1 2026 Earnings: Wider-Than-Expected Losses as Shares Gain 11.33%Balance Sheet Strength - vinanet.vn
Tempest Therapeutics (TPST) Stock Forum and Discussion - Moomoo
TPST Q1 2026 Earnings: EPS Deeply Misses Estimates as No Revenue ReportedPositive Surprise Momentum - Vinanet
TPST Q1 2026 Earnings: Clinical-Stage Biotech Reports Deep EPS Miss as Shares Slide 13.25%EPS Surprise History - vinanet.vn
Tempest Therapeutics Cash Drops to $0.8M Amid Recent Asset Acquisition - Minichart
Tempest Therapeutics Secures Up to $50 Million Equity Facility From Lincoln Park - Minichart
Tempest Therapeutics Cash Drops to $0.8 Million, Raising Going-Concern Risk - Minichart
Form 8K Tempest Therapeutics Inc For: 13 August By Investing.com - Investing.com Nigeria
Tempest Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Tempest Therapeutics Secures Flexible $50 Million Equity Facility - TipRanks
Tempest Therapeutics Q2 loss narrows to $5.2m; advances CAR-T pipeline - scanx.trade
Tempest Therapeutics (TPST) expands CAR-T pipeline amid $32.9M loss and cash strain - Stock Titan
Tempest Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Tempest Therapeutics Announces Senlang Collaboration to Advance TPST-4003 In Vivo CAR-T Pipeline and Appoints Two New Directors - Quiver Quantitative
Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update - Yahoo Finance
Tempest Therapeutics Inc (TPST) Earnings, Actual EPS, EPS Estimates & Results - Stocktwits
Tempest Therapeutics (TPST) Surges 13% as Biotech Momentum Builds Above Key SupportAnalyst Downgrade Signals - vinanet.vn
Tempest Therapeutics Inc expected to post a loss of 30 cents a shareEarnings Preview - TradingView
Tempest Therapeutics (TPST) Gains 3% as Biotech Stock Holds Ground Above $0.86 SupportFactor Momentum - vinanet.vn
Tempest Therapeutics (TPST) Slides to $0.86, Testing Support Near $0.82Range Breakout - vinanet.vn
Tempest Therapeutics (TPST) Shows Modest Uptick, Holding Above Key SupportPrice Target - vinanet.vn
Tempest Therapeutics Inc (TPST) Institutional Confidence - TradingKey
Tempest Therapeutics Adjourns Vote on Governance Changes - TipRanks
Tempest Therapeutics Inc (TPST) Cash Flow - TradingKey
TPST|Tempest Therapeutics Inc|Price:0.942|Chg%:+0.016 - TradingKey
Tempest Therapeutics Inc (TPST) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TradingKey - TradingKey
Tempest Therapeutics Inc (TPST) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Tempest Therapeutics, Inc. Revenue Breakdown – NASDAQ:TPST - TradingView
Tempest Therapeutics Inc (TPST) Valuation: PE, PB & Fair Value Analysis - TradingKey
TPST Q1 2026 Earnings: Wide EPS Miss Highlights Cash Burn ChallengesEarnings Growth Forecast - vinanet.vn
Tempest Therapeutics (TPST) Slightly Declines as Stock Nears Support LevelBuy Signal Reports - dars.gov.et
Tempest Therapeutics inks China in vivo CAR-T deal - TipRanks
Tempest Therapeutics, Inc. and Heibei Senlang Biotechnology Co., Ltd. Enter into Product Development and Investigator-Initiated Trial Collaboration Agreement - marketscreener.com
Tempest Therapeutics (TPST) Pulls Back to $0.97, Testing Key SupportSign of Weakness - dars.gov.et
Tempest Therapeutics Announces Strategic Partnership with Senlang to Advance TPST-4003 into First-in-Human Study in Autoimmune Diseases - Quiver Quantitative
Tempest Therapeutics Inc Azioni (TPST) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):